🎯 Module 01 · Therapeutic Area Strategy

Therapeutic Area Strategy Matrix

TA-level attractiveness × internal capability matrix. Identify which therapeutic areas to invest in, harvest, divest, or partner across the corporate portfolio.

Active TAs

6

across portfolio

Invest TAs

2

Oncology · Immunology

Harvest TAs

2

Cardiometabolic · CNS

Divest TAs

1

Anti-infectives

📊 TA Attractiveness × Capability Matrix

Bubble size = current annual revenue. Quadrant placement drives strategic action.

🎯 TA Strategic Classification

Therapeutic Area	Current Revenue	5-Yr CAGR	Market Attractiveness	Internal Capability	Strategic Action
Oncology	$4.8B	+18%	92	88	Invest · Lead
Immunology / Inflammation	$2.1B	+12%	85	78	Invest · Build
Rare Disease	$840M	+22%	82	62	Partner · BD&L
Cardiometabolic	$1.8B	+4%	62	85	Harvest · Selective
CNS / Neurology	$680M	+2%	58	68	Harvest · LCM only
Anti-Infectives	$320M	-3%	38	42	Divest · Spin-out

⚡ TA Strategy Strategic Brief

Portfolio mix is over-concentrated in Cardiometabolic and CNS (combined 19% of revenue but only 6% of growth). Recommended portfolio reshaping:

Invest (Oncology, Immunology): Increase R&D allocation from 58% to 68% by Year 3. Three Phase 2 ICIs and two TIGIT-class assets warrant accelerated investment.
Partner (Rare Disease): High attractiveness, weak capability. Pursue 1-2 in-licensing deals annually to build capability. RD-901 (Pompe) is candidate Tier-1 deal.
Harvest (Cardiometabolic, CNS): Reduce new R&D spend by 60%. Fund only lifecycle management (formulation, fixed-dose combo, pediatric indications). Maintain commercial franchise for cash flow.
Divest (Anti-Infectives): Sub-scale franchise underperforming growth and capability. Spin-out or asset-sale to specialty player (Pfizer, GSK have prior anti-infective M&A interest). Estimated divestiture value $1.2-1.6B.

🏢 Module 02 · M&A Strategy

M&A Target Screener

Screen biopharma acquisition targets against strategic fit, asset quality, financial accretion, and execution feasibility. Prioritize 3-5 highest-value targets for active engagement.

Targets Screened

42

market cap $500M-$15B

High-Fit Targets

6

composite ≥ 80

Available Capital

$18B

cash + capacity

Tax-Optimized Headroom

$24B

w/ debt issuance

🎯 Top 10 M&A Targets

Target	Ticker	Market Cap	Key Asset(s)	TA Fit	Strategic Score	Premium Est.	Verdict
Verve Therapeutics	VERV	$1.2B	Gene editing (PCSK9)	Cardio	88	40%	Pursue · Tier 1
Crinetics Pharma	CRNX	$3.8B	Paltusotine (acromegaly)	Rare	86	35%	Pursue · Tier 1
Cytokinetics	CYTK	$5.2B	Aficamten (HCM)	Cardio	82	40%	Pursue · Tier 1
Revolution Medicines	RVMD	$8.2B	RMC-6236 (RAS multi)	Oncology	85	45%	Pursue · Tier 1
Nuvation Bio	NUVB	$680M	Taletrectinib (ROS1)	Oncology	76	50%	Watch
Praxis Precision	PRAX	$1.4B	Ulixacaltamide (tremor)	CNS	72	35%	Watch
Iovance Biotherapeutics	IOVA	$1.8B	Lifileucel (TIL therapy)	Oncology	68	30%	Watch
Arcus Biosciences	RCUS	$1.6B	Domvanalimab (TIGIT)	Oncology	62	25%	Pass · partnered
Vir Biotechnology	VIR	$1.1B	HBV/HDV portfolio	Infectious	52	N/A	Pass · off-strategy
Mersana Therapeutics	MRSN	$220M	UpRi (HER2-low ADC)	Oncology	48	N/A	Pass · low quality

⚡ M&A Strategic Brief

Four Tier-1 targets identified with composite scores ≥ 82. Sequencing recommendation:

Crinetics Pharma (acromegaly): Builds rare disease franchise quickly. Paltusotine is first-in-class oral acromegaly. $3.8B market cap + 35% premium = ~$5.1B transaction. Highest-confidence Tier 1.
Verve Therapeutics (gene editing): Platform play — gene editing capabilities transfer across cardio, rare. $1.2B + 40% = ~$1.7B small bolt-on with significant strategic optionality.
Cytokinetics (HCM): Aficamten is best-in-class HCM therapy. Adds new cardio franchise growth driver. $5.2B + 40% = ~$7.3B transaction.
Revolution Medicines (RAS-multi): Highest scientific quality target. RMC-6236 is breakthrough RAS asset with multi-billion peak potential. $8.2B + 45% = ~$11.9B — most expensive but highest upside.

Capital constraint: Total Tier-1 transaction cost ~$26B exceeds $24B headroom. Recommend Crinetics + Verve + Cytokinetics first ($14.1B); revisit Revolution Medicines after cardio franchise integration.

💼 Module 03 · Capital Allocation

Capital Allocation Optimizer

Optimal capital deployment across R&D, BD&L, M&A, share buybacks, and dividends. Maximize 5-year EPS growth and ROIC while maintaining strategic optionality.

Annual FCF

$8.4B

free cash flow

R&D Investment

$5.2B

22% of revenue

BD&L Budget

$3.2B

annual capacity

Return to Shareholders

$4.8B

dividends + buybacks

🥧 Current Capital Allocation

🎯 Recommended Allocation

📊 Capital Allocation Detail by Use

Use of Capital	Current ($B)	Recommended ($B)	Δ	Expected ROIC	Strategic Priority
R&D — Discovery & Preclinical	$1.4	$1.2	-$0.2	8-12%	Selective
R&D — Clinical Development	$3.8	$4.4	+$0.6	14-22%	Increase
BD&L (Licenses + Partnerships)	$1.2	$1.8	+$0.6	16-25%	Increase
M&A (Targeted Acquisitions)	$2.0	$3.6	+$1.6	12-18%	Increase
Capex (Manufacturing + Digital)	$1.6	$1.8	+$0.2	10-14%	Stable
Dividends	$2.4	$2.4	$0.0	N/A	Stable
Share Buybacks	$2.4	$1.6	-$0.8	N/A	Reduce

⚡ Capital Allocation Strategic Brief

Recommended reallocation shifts $1.6B from buybacks + discovery R&D into M&A + late-stage development + BD&L, raising portfolio ROIC from 14% to 17% over 5 years.

Reduce share buybacks ($-0.8B): Current trading at ~16× forward earnings is fair value, not undervalued. Better return on capital available in M&A and clinical development.
Reduce discovery R&D ($-0.2B): Internal discovery has 5% PTRS to launch vs. 35% PTRS for Ph2 in-licensed assets. Shift internal discovery to platform technologies (gene editing, ADC).
Increase late-stage clinical ($+0.6B): Three Phase 3 readiness gates need additional investment to maintain timelines.
Increase M&A ($+1.6B): Capacity for 1-2 Tier-1 acquisitions per year. Crinetics + Verve combination is feasible within this envelope.

🏆 Module 04 · Competitive Positioning

Competitive Positioning Analysis

Multi-dimensional company-level competitive analysis against top biopharma peers. Identify positioning gaps, white-space opportunities, and defensive vulnerabilities.

Peer Set Size

12

global biopharma

Rev Rank

#9

of 12 peers

Pipeline Rank

#6

composite NPV

▲ +2 vs LY

R&D Productivity

#4

PTRS-weighted

🕸️ Competitive Positioning Radar

📊 Peer Comparison — Top Metrics

Company	Revenue	R&D %	Pipeline NPV	Onc	Imm	Cardio	Rare	5-Yr CAGR
Pfizer	$59B	18%	$28B	✓✓✓	✓✓	✓✓	✓	+4%
Merck	$60B	25%	$32B	✓✓✓	✓	✓✓		+8%
AbbVie	$54B	14%	$24B	✓✓	✓✓✓		✓	+5%
Bristol Myers Squibb	$45B	22%	$22B	✓✓✓	✓✓	✓	✓	+3%
AstraZeneca	$45B	22%	$28B	✓✓✓	✓	✓✓	✓✓	+12%
Roche	$67B	20%	$30B	✓✓✓	✓	✓	✓	+5%
Novartis	$48B	21%	$22B	✓✓	✓✓	✓✓	✓✓✓	+6%
This Company	$22B	22%	$14B	✓✓✓	✓✓	✓	✓	+9%
GSK	$38B	15%	$16B	✓✓	✓		✓	+5%
Eli Lilly	$36B	26%	$32B	✓✓	✓✓	✓✓✓	✓	+22%
Sanofi	$45B	15%	$18B	✓	✓✓✓	✓	✓✓	+4%
Takeda	$31B	14%	$14B	✓✓	✓✓		✓✓✓	+2%

⚡ Competitive Positioning Brief

Company ranks #9 in revenue but #6 in pipeline NPV — pipeline is over-indexed vs. current revenue, signaling positive forward growth trajectory. Three competitive priorities:

Defend Oncology leadership: Tied with Pfizer / Merck / BMS / AZ / Roche at "✓✓✓" oncology — must invest aggressively to maintain top-tier positioning. ASC-301 launch is critical.
Close Immunology gap: AbbVie (✓✓✓) and Sanofi (✓✓✓) lead. Recommend either organic build via IMD-118 + IMD-256 OR M&A of mid-cap immunology player.
Rare disease whitespace: Significant peer gap — Novartis, AZ, Takeda lead. Crinetics M&A would move Rare from ✓ to ✓✓, narrowing peer gap meaningfully.

📅 Module 05 · Long-Range Plan

5-Year Strategic Roadmap (LRP)

Integrated 5-year long-range plan covering revenue trajectory, pipeline transitions, M&A milestones, and strategic positioning evolution.

2026 Revenue

$22B

current

2031 Revenue Target

$38B

+11.5% CAGR

2031 EPS

$18.40

+13% CAGR

Cumulative Inv

$42B

R&D + M&A + BD&L

📈 5-Year Revenue Bridge

🗺️ Strategic Milestone Roadmap

ASC-301 NSCLC launch

2027

IMD-118 UC Phase 3 readout

Q2 2028

Crinetics acquisition close

Q3 2027

Verve gene editing close

Q4 2027

Anti-infectives divestiture

Q1 2028

IMD-118 UC launch

2029

IRA Medicare price impact (Cohort 1)

Q1 2028

Cytokinetics acquisition (optional)

2030

RD-901 Pompe ERT launch

2030

Revolution Med acquisition (revisit)

2031

⚡ LRP Strategic Brief

Base-case LRP delivers $38B revenue by 2031 (+11.5% CAGR) and EPS $18.40 (+13% CAGR), top-quartile growth among large-cap biopharma peers. Critical execution dependencies:

2027 — Launch year: ASC-301 NSCLC + Crinetics close = $1.8B incremental revenue contribution in Year 1. Most consequential year.
2028 — Pivotal year: IMD-118 Phase 3 readout determines immunology trajectory; IRA negotiation begins. Worst-case scenario: IMD-118 fails + 40% IRA cut = $4.2B revenue gap vs plan.
2029-2030 — Build year: IMD-118 launch + RD-901 + Cytokinetics integration. Diversifies portfolio beyond Onc + immunology dependence.
2031 — Optimization year: Revolution Medicines acquisition decision based on RAS-multi data and cardio synergies post-Cytokinetics.

Risk-adjusted LRP achieves $34B revenue by 2031 (+9% CAGR). Stretch case with all M&A executed and zero Phase 3 failures: $42B (+14% CAGR).